Search
Search Results
-
Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin
BackgroundCis-diamminedichloro-platinum (CDDP)-based chemotherapy regimens are the most predominant treatment strategies for patients with esophageal...
-
Dihydroartemisinin abolishes cisplatin-induced nephrotoxicity in vivo
Dihydroartemisinin (DHA), a derivative of artemisinin which is primarily used to treat malaria in clinic, also confers protective effect on...
-
Low-dose metronomic cisplatin as an antiangiogenic and anti-inflammatory strategy for cancer
BackgroundConventional chemotherapy is based on the maximum tolerated dose (MTD) and requires treatment-free intervals to restore normal host cells....
-
Carbon nanotubes conjugated with cisplatin activate different apoptosis signaling pathways in 2D and 3D-spheroid triple-negative breast cancer cell cultures: a comparative study
The type of experimental model for the in vitro testing of drug formulations efficiency represents an important tool in cancer biology, with great...
-
N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation
BackgroundCisplatin (CDDP) is the first-line chemotherapeutic strategy to treat patients with ovarian cancer (OC). The development of CDDP resistance...
-
TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer
Cisplatin (CDDP)-based chemotherapy is commonly used to treat advanced non-small cell lung cancer (NSCLC). However, the efficacy is limited by the...
-
MicroRNAs as the pivotal regulators of cisplatin resistance in head and neck cancers
Although, there is a high rate of good prognosis in early stage head and neck tumors, about half of these tumors are detected in advanced stages with...
-
MicroRNAs as the critical regulators of autophagy-mediated cisplatin response in tumor cells
Chemotherapy is one of the most common therapeutic methods in advanced and metastatic tumors. Cisplatin (CDDP) is considered as one of the main...
-
EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance
BackgroundCisplatin (CDDP)-based chemotherapy is a standard first-line treatment for metastatic bladder cancer (BCa) patients, and chemoresistance...
-
Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state
BackgroundCisplatin (CDDP) is a mainstay treatment for advanced head and neck squamous cell carcinomas (HNSCC) despite a high frequency of innate and...
-
Increased HRD score in cisplatin resistant penile cancer cells
Background/IntroductionPenile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5...
-
Concomitant palonosetron ameliorates cisplatin-induced nephrotoxicity, nausea, and vomiting: a retrospective cohort study and pharmacovigilance analysis
BackgroundCisplatin (CDDP)-induced nephrotoxicity is the most important complication of CDDP treatment. 5-Hydroxytryptamine type 3 receptor...
-
Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p
Bladder cancer (BC) is one of the most common malignant tumors of the urinary system, and cisplatin (CDDP) is a critical chemical drug for the...
-
Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside
BackgroundPeritoneal metastases from colorectal cancer (CRCPM) are related to poor prognosis. Cytoreductive surgery (CRS) and hyperthermic...
-
α-Catenin acetylation is essential for its stability and blocks its tumor suppressor effects in breast cancer through Yap1
α-Catenin plays a critical role in tissue integrity, repair, and embryonic development. However, the post-translational modifications of α-catenin...
-
KRAS is a molecular determinant of platinum responsiveness in glioblastoma
BackgroundKRAS is the undisputed champion of oncogenes, and despite its prominent role in oncogenesis as mutated gene, KRAS mutation appears...
-
Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients
BackgroundRadio-chemotherapy with CDDP is the standard for H&N squamous cell cancer. CDDP 100 mg/m 2 /q3 is the standard; alternative schedules are...
-
Study on the activation of cell death mechanisms: in search of new therapeutic targets in glioblastoma multiforme
Malignant primary brain tumors remain among the most difficult cancers to treat, in particular, Glioblastoma Multiforme (GBM) is the deadliest brain...
-
p53 dry gene powder enhances anti-cancer effects of chemotherapy against malignant pleural mesothelioma
Dry gene powder is a novel non-viral gene-delivery system, which is inhalable with high gene expression. Previously, we showed that the transfection...
-
Co-delivery of gemcitabine and cisplatin via Poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) micelle to improve the in vivo stability and antitumor effect
PurposeThe intention of the study was to co-delivery gemcitabine and cisplatin with totally different nature by prodrug and micelle strategy to...
